Reducing cardiac events after acute coronary syndromes

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 5, 2004, Pages

  Granger, Christopher B ^a   Weaver, W Douglas ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Anticoagulation; ESTEEM; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LIVER DYSFUNCTION; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; ASPIRIN; AZETIDINES; BENZYLAMINES; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS;

EID: 12344278902     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349(9061):1269-1276.
2. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Tex.:American Heart Association;2002.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevaton myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/angina.pdf.
4. Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol. 2001;37:1571-1580.
5. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281(8):707-713.
6. Bahit CM, Granger CB, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. Am Heart J. 2002;143:205-216.
7. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-1672.
8. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
9. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12.
10. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103:604-616.
11. Van Belle E, Lablanche JM, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation. 1998;97:61-68.
12. Merlini PA, Bauer KA, Oltana L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
13. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701-707.
14. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
15. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. J Am Coll Cardiol. 2001;37(4):1001-1007.
16. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502.
17. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004; 292:89-96.
18. Kottke-Marchant K, Bahit MC, Granger CB, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO IIb haemostatis substudy. Eur Heart J. 2002;23:1202-1212.
19. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359(9313):294-302.
20. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347;969-974.
21. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.
22. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.